Search

Background/Objectives: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults. However, vaccination can be an effective preventative measure. This Phase 3 study (NCT05158140) assessed the immunogenicity and safety of co-administering the SARS-CoV-2 vaccine mRNA-1273 with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or the 15-valent pneumococcal conjugate vaccine (PCV15). Methods: Participants were healthy adults ≥50 years of age who had previously received a two-dose primary series of mRNA-1273 ≥5 months before the first study visit and may have received a booster dose of mRNA-1273 ≥4 months prior to the first study visit. Participants were randomized (1:1:1:1) to receive mRNA-1273 concomitantly with PPSV23 or PCV15 on Day 1 followed by placebo on Day 30, or sequentially with mRNA-1273 and placebo on Day 1 and PPSV23 or PCV15 on Day 30. The primary study endpoints were pneumococcal-serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) and SARS-CoV-2-specific binding antibody GMTs at 30 days after vaccination, as well as safety and tolerability following vaccination. Results: In total, 850 adults participated in the study. Serotype-specific OPA GMTs at 30 days post-vaccination with PPSV23 or PCV15 were generally comparable between the concomitant and sequential groups. SARS-CoV-2-specific GMTs increased in all groups from pre-vaccination to 30 days post-vaccination with mRNA-1273, with a consistent response between concomitant and sequential groups. Safety profiles were comparable across study groups. Conclusions: Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated. [ABSTRACT FROM AUTHOR]

Prisoners in the Arizona Department of Corrections, Rehabilitation, and Reentry (ADCRR) coordinate to circumvent full racial housing integration, revealing how "race" and adherence to the "racial code" is used as an organizing concept in carceral settings that is distinct from conceptualizations of race and politics of identity within free society. In addition to providing a review of the literature on the complexity of prison racialization, we base our discussion of racialization and adherence to the racial code on our combined experience as formerly racialized and gang-affiliated inmates, as well as on insights from informal and semi-structured interviews with prisoners who have navigated attempts at racial integration as part of the ADCRR's recently adopted Integrated Housing Program. [ABSTRACT FROM AUTHOR]

Putting research and reflection on prison experience into conversation with the subfields of carceral and health geography, we discuss the "somatic carceral condition" as a viseral, bodily effect of prisonization. In doing so, we call for increased reliance on data derived from somatic experience as well as autoethnographic insight on imprisonment. More broadly, we argue, an embrace of somatic data used to tell the story of marginalization and captivity experienced in prison and across the carceral continuum can help advance the discipline of geography theoretically, methodologically, and in terms of contributing to praxis-based interventions. [ABSTRACT FROM AUTHOR]